CollPlant Biotechnologies Ltd. (CLGN) has released an update.
CollPlant Biotechnologies Ltd. reports a successful 2023 with key advancements in their dermal filler and regenerative breast implant programs, and a solid end-of-year financial position boasting $26.7 million in cash. Strategic collaborations, including one with AbbVie that triggered a $10 million payment, and a joint effort with Stratasys to bio-fabricate human tissues, have positioned CollPlant for an optimistic 2024 in the aesthetics and regenerative market. The company also highlights a significant patent grant in the U.S. and progress in their ESG initiatives.
For further insights into CLGN stock, check out TipRanks’ Stock Analysis page.
